Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.

@article{Izzo2015EndocannabinoidsAT,
  title={Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.},
  author={Angelo A. Izzo and Giulio G. Muccioli and Michael R. Ruggieri and Rudolf Schicho},
  journal={Handbook of experimental pharmacology},
  year={2015},
  volume={231},
  pages={
          423-47
        }
}
Components of the so-called endocannabinoid system, i.e., cannabinoid receptors, endocannabinoids, as well as enzymes involved in endocannabinoid synthesis and degradation, have been identified both in the gastrointestinal and in the urinary tract. Evidence suggests that the endocannabinoid system is implicated in many gastrointestinal and urinary physiological and pathophysiological processes, including epithelial cell growth, inflammation, analgesia, and motor function. A pharmacological… Expand
The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease
TLDR
It was not surprising to discover that the GI tract accommodates and expresses all the components of the ECS, a physiologic entity that controls tissue homeostasis with the help of endogenously produced CBs and their receptors. Expand
Endocannabinoids in Bladder Sensory Mechanisms in Health and Diseases
TLDR
Results suggest a high potential of cannabinoids to therapeutically ameliorate lower urinary tract symptoms in overactive bladder and painful bladder syndromes and significant potential for these novel therapeutics which are devoid of central nervous system psychotropic actions, and which may avoid many of the side effects of current treatments. Expand
Medical Cannabis and Cannabinoids: An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon?
TLDR
This review is an update on the role of cannabinoids in intestinal inflammation and carcinogenesis and a discussion on their potential therapeutic use. Expand
Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer
TLDR
The molecular changes of the endocannabinoid system in the pathologies of the large intestine, focusing on inflammation and cancer are described, to form a comprehensive understanding of cannabinoid interactions in colorectal cancer and intestinal bowel diseases. Expand
The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients.
TLDR
CBDV exerts intestinal anti-inflammatory effects in mice via TRPA1, and in children with active UC, and has a favorable safety profile in humans, which may be considered for possible clinical trials in patients with UC. Expand
Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing
TLDR
The present review focuses on the direct and indirect endocannabinoid receptor agonism by PEA and its analogues and also targets the main findings from experimental and clinical studies on ALIAmides in animal health and wellbeing. Expand
Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation
TLDR
Preclinical data support a novel strategy of combining these substances for the potential development of a treatment of inflammatory bowel disease and highlight the apparent additivity between phytocannabinoids and FO. Expand
Cannabimimetic phytochemicals in the diet – an evolutionary link to food selection and metabolic stress adaptation?
  • J. Gertsch
  • Biology, Medicine
  • British journal of pharmacology
  • 2017
TLDR
It is postulated that the mismatch of ancient lipid genes of hunter‐gatherers and pastoralists with the high‐carbohydrate diet introduced by agriculture could be compensated for via dietary modulation of the ECS. Expand
An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse
TLDR
CBD BDS, given after the inflammatory insult, attenuates injury and motility in intestinal models of inflammation and sustain the rationale of combining CBD with other minor Cannabis constituents and support the clinical development of CBD BDS for IBD treatment. Expand
Potential Future Pharmacological Treatment of Bladder Dysfunction.
  • K. Andersson
  • Chemistry, Medicine
  • Basic & clinical pharmacology & toxicology
  • 2016
TLDR
Evidence suggests that components of the endocannabinoid system are involved in regulation of bladder function, but the roles of these channels for normal function and in pathological states have not been established, and so far adverse effects (hyperthermia) have hampered development of antagonists. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 156 REFERENCES
Cannabinoids and the gut: new developments and emerging concepts.
TLDR
Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric infections and inflammatory conditions to disorders of motility, emesis and abdominal pain, with recent data on genetic mutations in the endocannabinoid system in GI disease highlighted. Expand
The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.
TLDR
The ECS is implicated in gut homeostasis, modulating gastrointestinal motility, visceral sensation, and inflammation, as well as being recently implicated in IBD pathogenesis. Expand
Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies
TLDR
An introduction into the functions of the endocannabinoid system in the GI tract is given, the role of the ECS in GI diseases is highlighted, and its potential pharmacological exploitation is addressed. Expand
Cannabinoids and gastrointestinal motility: animal and human studies.
TLDR
Modulation of the gut endogenous cannabinoid system may provide a useful therapeutic target for disorders of gastrointestinal motility. Expand
Distribution and function of monoacylglycerol lipase in the gastrointestinal tract.
The endogenous cannabinoid system plays an important role in the regulation of gastrointestinal function in health and disease. Endocannabinoid levels are regulated by catabolic enzymes. Here, weExpand
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
  • F. Borrelli, A. Izzo
  • Biology, Medicine
  • Best practice & research. Clinical endocrinology & metabolism
  • 2009
TLDR
Modulation of AE levels in the gut may provide new pharmacological strategies not only for the treatment of feeding disorders but also for the prevention or cure of widespread intestinal diseases such as inflammatory bowel disease and colon cancer. Expand
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.
TLDR
Anandamide is elevated in the inflamed colon of patients with ulcerative colitis, as well as in animal models of IBDs, to control inflammation, and elevation of its levels with inhibitors of its cellular reuptake might be used in the treatment of I BDs. Expand
Cannabinoids in intestinal inflammation and cancer.
TLDR
Pharmacological elevation of endocannabinoid levels may be a promising strategy to counteract intestinal inflammation and colon cancer. Expand
Possible endocannabinoid control of colorectal cancer growth.
TLDR
Endocannabinoid levels are enhanced in transformed colon mucosa cells possibly to counteract proliferation via CBRs, and inhibitors of endocannabinoids inactivation may prove useful anticancer agents. Expand
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
TLDR
Cannabidiol, a likely safe compound, prevents experimental colitis in mice and reduces colon injury and endocannabinoid changes associated with 2,4,6-dinitrobenzene sulfonic acid administration. Expand
...
1
2
3
4
5
...